Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Comparison of the Effects of 2 Therapeutic Plasmapheresis Techniques: Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). A Monocentric Prospective Study With a Single-Case Experimental Design

CIDP, a rare disorder affecting young adults, causes gradual weakness of the limbs, areflexia and impaired sensory function. New CIDP phenotypes without antibodies but with modified cell profiles have been described. Treatments include corticotherapy, IVIg and plasmapheresis but the latter's action mechanisms remain unclear. Plasmapheresis supposedly removes toxic agents like antibodies from plasma but it is uncertain whether it has an immune-modulating effect. Also, the refining mechanisms of the two main plasmapheresis techniques - single plasma exchange and double filtration plasmapheresis (DFPP) - are different and unclear. This study aims to compare the evolution of peripheral lymphocyte profiles in patients with CIDP according to their treatment (single centrifugation plasmapheresis or DFPP) to better grasp the action mechanisms of both techniques.

Inclusion Criteria:

• Patients with confirmed Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) without pathogenic antibodies and stable under therapeutic plasmapheresis with one session every 2-3 weeks for at least two months.
• Patients who have given free written informed consent.
• Patients who have signed the consent form.
• Patients affiliated to or beneficiaries of a health insurance scheme.
• Adult patients (≥18 ans).
• Healthy subjects of the same age and sex

Exclusion Criteria:

• Patients Under the age of 18.
• Patients under immunosuppressive treatment for less than 3 months.
• Patients participating in Category 1 research involving human subjects.
• Patients in an exclusion period determined by another study.
• Patients under legal protection, guardianship or curatorship.
• Patients unable to express consent.
• Patients for whom it is impossible to give informed information.
• Pregnant, parturient or breastfeeding patients.
• Healthy subject with chronic pathology or drug treatment